Curated News
By: NewsRamp Editorial Staff
June 24, 2026

VERAXA Biotech Reports Promising BiTAC-ADC Data for Targeted Cancer Therapy

Discuss on Substack
Original Source

TLDR

  • VERAXA Biotech's new BiTAC-ADC data shows selective cancer cell killing, offering a competitive edge in precision oncology.
  • VERAXA's BiTAC-ADC technology activates therapeutic effects only in targeted tumor cells, sparing healthy cells in lab tests.
  • VERAXA's targeted cancer therapy aims to improve patient outcomes by reducing harm to healthy cells.
  • VERAXA Biotech is presenting its BiTAC-ADC and BiTAC-TCE platforms at BIO 2026 for potential collaborations.

Impact - Why it Matters

This development matters because it addresses a critical challenge in oncology: improving the precision of cancer treatments to reduce side effects. VERAXA's BiTAC-ADC platform could lead to therapies that selectively kill cancer cells while minimizing damage to healthy cells, potentially improving patient outcomes and quality of life. As the company seeks partnerships at BIO 2026, this technology represents a step forward in the next generation of antibody-based cancer therapies, which may offer more effective and safer options for patients with solid tumors like breast cancer.

Summary

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego. The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results highlight the potential of VERAXA's proprietary BiTAC approach, which aims to activate therapeutic effects only in targeted tumor cells, sparing healthy tissues.

VERAXA’s diversified oncology pipeline includes antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other antibody-based formats. The company recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. At the upcoming BIO International Convention, VERAXA will present its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations, seeking partners to advance these next-generation therapies toward clinical development.

For investors seeking the latest news and updates relating to VRXA, the company’s newsroom is available at https://nnw.fm/VRXA. NetworkNewsWire (NNW), a specialized communications platform, distributed this news as part of its services for private and public companies. NNW is one of over 75 brands within the Dynamic Brand Portfolio @ IBN, offering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Reports Promising BiTAC-ADC Data for Targeted Cancer Therapy

blockchain registration record for this content.